Table I.

Patient Characteristics

	11q- Only (N=247)	17p- Only (N=158)	Both (N=20)	Neither (N=1759)	Total (N=2184)
Gender
female	67 (27.1%)	66 (41.8%)	5 (25.0%)	571 (32.5%)	709 (32.5%)
male	180 (72.9%)	92 (58.2%)	15 (75.0%)	1188 (67.5%)	1475 (67.5%)
Survival Status
Alive	150 (60.7%)	77 (48.7%)	6 (30.0%)	1322 (75.2%)	1555 (71.2%)
Dead	97 (39.3%)	81 (51.3%)	14 (70.0%)	437 (24.8%)	629 (28.8%)
Clinical Stage (Rai) at Diagnosis
Missing	22	14	1	117	154
Rai 0: Low risk	93 (41.3%)	73 (50.7%)	5 (26.3%)	917 (55.8%)	1088 (53.6%)
Rai 1 or 2: Intermediate risk	114 (50.7%)	59 (41.0%)	9 (47.4%)	653 (39.8%)	835 (41.1%)
Rai 3 or 4: High risk	18 (8.0%)	12 (8.3%)	5 (26.3%)	72 (4.4%)	107 (5.3%)
CD38
Missing	21	11	1	176	209
Negative	102 (45.1%)	87 (59.2%)	9 (47.4%)	1151 (72.7%)	1349 (68.3%)
Positive	124 (54.9%)	60 (40.8%)	10 (52.6%)	432 (27.3%)	626 (31.7%)
IGHV Mutation Status
Missing	72	46	4	672	794
Mutated	31 (17.7%)	31 (27.7%)	4 (25.0%)	671 (61.7%)	737 (53.0%)
Unmutated	144 (82.3%)	81 (72.3%)	12 (75.0%)	416 (38.3%)	653 (47.0%)
ZAP70
Missing	61	32	4	434	531
Negative	84 (45.2%)	49 (38.9%)	8 (50.0%)	859 (64.8%)	1000 (60.5%)
Positive	102 (54.8%)	77 (61.1%)	8 (50.0%)	466 (35.2%)	653 (39.5%)
Treatment Status*
Not treated	64 (25.9%)	29 (18.4%)	2 (10.0%)	1027 (58.4%)	1122 (51.4%)
Treated	183 (74.1%)	129 (81.6%)	18 (90.0%)	732 (41.6%)	1062 (48.6%)
Age at Diagnosis
N	247	158	20	1759	2184
Median (years)	59.9	61.5	63.6	62.6	62.2
Q1, Q3 (years)	52.6, 67.7	54.0, 70.2	54.4, 68.8	54.3, 70.3	54.1, 70.0
Range (years)	(21.9–89.1)	(33.2–84.7)	(35.3–78.0)	(28.0–92.9)	(21.9–92.9)
Years Between Diagnosis & Sentinel FISH
N	247	158	20	1759	2184
Median	1.8	3.2	3.5	0.3	0.5
Q1, Q3	0.1, 5.8	0.2, 7.0	1.2, 7.8	0.0, 4.0	0.1, 4.4
Range	(0.0–36.3)	(0.0–31.0)	(0.0–26.1)	(0.0–43.8)	(0.0–43.8)

^*Treatment status was assessed at time of censor date

FISH, fluorescence in situ hybridization